Healthcare
Kiniksa Pharmaceuticals, Ltd.(KNSA)
Live Price
Offline$55.11
+1.66% today
1Y Change
+91.01%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $4.00B
- Revenue Growth
- +60.1%
- EPS Growth
- +233.3%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Healthcare stock with a market cap of $4.00B and listed on NASDAQ. The stock last traded around $55.11 and up 91.0% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +60.1%, EPS growth of +233.3%, a dividend yield of 0.0%. What stands out right now is revenue +60.1%, EPS +233.3%, free cash flow 0.0% with operating margin 12.4% and ROIC 12.3%. Valuation already assumes a fairly strong business story at P/E 56.4 and price/sales 5.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines KNSA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+60.1% vs +7.6% peer median
Operating Margin
Below sector median
+12.4% vs +19.4% peer median
P/E
Above sector median
56.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +60.1% and EPS at +233.3%, with operating margin around 12.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +2.6% | +4.8% | -15.7% |
2026 Feb 24, 2026 | -41.4% | -1.7% | +4.3% | +3.3% |
2025 Oct 28, 2025 | -30.3% | -5.2% | -2.3% | +8.3% |
Benchmark Edge
KNSA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KNSA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KNSA Max Drawdown
-21.12%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KNSA and SPY.
Company Overview
Kiniksa Pharmaceuticals, Ltd.
NASDAQ Global Select
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
- Leadership
- Sanj K. Patel
- IPO Date
- May 25, 2018
- Employees
- 315
- Street Address
- Clarendon House
- Mailing
- Hamilton, HM 11
- Region
- Hamilton, BM
- Reporting Currency
- USD
- Investor Line
- 7814399100
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 56.4
- EV/EBITDA
- 37.6
- Price/Sales
- 5.3
- Price/Book
- 6.8
Growth
- Revenue
- +60.1%
- EPS
- +233.3%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 54.6%
- Operating Margin
- 12.4%
- Net Margin
- 9.7%
- ROE
- 13.3%
- ROIC
- 12.3%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 3.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.